Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2

被引：0

作者：

Kortuem, M. ^{[1
]}

Trudel, S. ^{[2
]}

Cohen, A. D. ^{[3
]}

Richardson, P. G. ^{[4
]}

Lonial, S. ^{[5
]}

Opalinska, J. B. ^{[6
]}

Gupta, I ^{[6
]}

Byrne, J. ^{[6
]}

Zhi, E. ^{[6
]}

Baron, J. ^{[6
]}

Morgan, L. ^{[6
]}

Voorhees, P. M. ^{[7
]}

Popat, R. ^{[8
]}

机构：

[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany

[2] Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[6] GlaxoSmithKline, Upper Providence, PA USA

[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[8] NHS Fdn Trust, Univ Coll London Hosp, London, England

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期

基金：

芬兰科学院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

203

引用

页码：97 / 98

页数：2

共 50 条

[21] Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
Eliason, Laurie
Correll, Julia
Martin, Mona
Cardellino, Anna
Opalinska, Joanna
Piontek, Trisha
Gorsh, Boris
Sapra, Sandhya
Popat, Rakesh
BLOOD, 2020, 136
[22] DREAMM-6: Safety, Tolerability and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM)
Popat, Rakesh
Nooka, Ajay
Stockerl-Goldstein, Keith
Abonour, Rafat
Ramaekers, Ryan
Khot, Amit
Forbes, Adam
Lee, Cindy
Augustson, Bradley
Spencer, Andrew
Mateos, Maria-Victoria
Chopra, Bikramjit
Rogers, Rachel
Smith, Deborah A.
Davidge, Jacqueline
de Oca, Rocio Montes
Ferron-Brady, Geraldine
Yeakey, Anne
Talekar, Mala
Kremer, Brandon E.
Gupta, Ira
Quach, Hang
BLOOD, 2020, 136
[23] Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Byrne, Julie
Eliason, Laurie
Scott, Emma
Opalinska, Joanna
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S425 - S425
[24] Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14
Salwender, Hans
Hultcrantz, Malin
Kleinman, Dave
Ghataorhe, Pavandeep
Mckeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne
Byrne, Julie
Eliason, Laurie
Scott, Emma
Opalinska, Joanna
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
[25] Pivotal DREAMM-2 Study: Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Refractory to Proteasome Inhibitors and Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 Monoclonal Antibodies (mAbs), Including Subgroups with Renal Impairment (RI) and High-Risk (HR) Cytogenetics
Lonial, Sagar
Lee, Hans Chulhee
Badros, Ashraf
Trudel, Suzanne
Nooka, Ajay K.
Chari, Ajai
Abdallah, Al-Ola
Callander, Natalie Scott
Sborov, Douglas Weston
Suvannasankha, Attaya
Weisel, Katja
Voorhees, Peter M.
Hultcrantz, Malin
Libby, Edward N.
Richardson, Paul G.
Otero, Paula Rodriguez
Besemer, Britta
Facon, Thierry
Hoos, Axel
Zhi, Eric
Baron, January
Piontek, Trisha
Jewell, Roxanne C.
Lewis, Eric
Opalinska, Joanna
Gupta, Ira
Cohen, Adam D.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S301 - S302
[26] No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Lowther, Daniel E.
Houseman, E. Andres
Han, Gang
Kleanthous, Eleni
Knoblock, Dawson
Zhou, Xiangdong
Banerjee, Shreyan
Patel, Sagar
Figueroa, David
BLOOD, 2022, 140
[27] Characterization of Ocular Adverse Events in Patients Receiving Belantamab Mafodotin (Belamaf) for ≥12 Months: Post Hoc Analysis of DREAMM-2 Study in Relapsed/Refractory Multiple Myeloma (RRMM)
Lonial, Sagar
Nooka, Ajay K.
Thulasi, Praneetha
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S.
Sborov, Douglas
Zaugg, Brian E.
Popat, Rakesh
Degli Esposti, Simona
Baron, January
Doherty, Allison
Lewis, Eric
Opalinska, Joanna
Paka, Prani
Piontek, Trisha
Gupta, Ira
Farooq, Asim V.
Jakubowiak, Andrzej
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S419 - S419
[28] Belantamab mafodotin concentration-QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM-1 and-2 studies
Jewell, Roxanne C.
Mills, Richard J.
Farrell, Colm
Visser, Sandra A. G.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 (10) : 2571 - 2581
[29] Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Byrne, Julie
Eliason, Laurie
Scott, Emma Catherine
Opalinska, Joanna
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[30] Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14
Hultcrantz, Malin
Kleinman, David
Ghataorhe, Pavandeep
McKeown, Astrid
He, Wei
Ling, Thomas
Jewell, Roxanne C.
Brunner, Joseph
Byrne, Julie
Eliason, Laurie
Scott, Emma
Opalinska, Joanna
BLOOD, 2021, 138

← 1 2 3 4 5 →